Thomas Marron, Director of the Early Phase Trials Unit, Professor of Medicine, Medical Oncology and Professor of Immunology and Immunotherapy shared a post on LinkedIn:
“As a Phase 1 doc I was always underwhelmed by the analysis of blood and tissue samples that patients graciously provided when they join a trial.
It’s a disservice to society to not learn from all trials, and leads to us giving up on many good drugs as we never learn how they work, so I was excited to help launch OCCAM out of Mount Sinai (yes I still work at Sinai!).
This week I had a great visit to our high-tech headquarters on the Hudson river. OCCAM is a non-profit Academic Research Organization (ARO, like a CRO but with world renowned cancer immunologists and bioinformaticians as your collaborators).
We work with small and large pharma to help get the most out of the precious bio specimens we collect during trials.”
Other articles about Blood Cancer on OncoDaily.